Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I

Anticancer Res. Jul-Aug 1989;9(4):889-91.

Abstract

Tumors of several organs have been shown to bear cell surface receptors for insulin-like growth factor I (IGF-I), and to exhibit dependence on this mitogen for optimum proliferation both in vivo and in vitro. To investigate the feasibility of a novel form of endocrine therapy that would exploit such dependence, we treated 8 patients with non-endocrine solid tumours with the somatostatin analogue SMS 201-995, in an effort to reduce growth hormone-stimulated IGF-I production. Significant decreases in basal and arginine-stimulated serum growth hormone and serum IGF-I were noted. This approach deserves evaluation as a potentially useful form of palliative endocrine therapy for certain cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arginine
  • Breast Neoplasms / drug therapy
  • Colonic Neoplasms / drug therapy
  • Female
  • Growth Hormone / blood*
  • Humans
  • Insulin-Like Growth Factor I / analysis*
  • Insulin-Like Growth Factor I / physiology
  • Kidney Neoplasms / drug therapy
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology
  • Octreotide / therapeutic use*
  • Ovarian Neoplasms / drug therapy
  • Pancreatic Neoplasms / drug therapy
  • Somatomedins / analysis*

Substances

  • Somatomedins
  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Arginine
  • Octreotide